InflaRx N.V. (IFRX): Price and Financial Metrics
IFRX Price/Volume Stats
| Current price | $1.40 | 52-week high | $7.25 |
| Prev. close | $1.40 | 52-week low | $1.14 |
| Day low | $1.40 | Volume | 1,050 |
| Day high | $1.40 | Avg. volume | 851,958 |
| 50-day MA | $2.07 | Dividend yield | N/A |
| 200-day MA | $3.30 | Market Cap | 62.59M |
IFRX Stock Price Chart Interactive Chart >
InflaRx N.V. (IFRX) Company Bio
Fireman B.V. (InflaRx) operates as a clinical-stage biopharmaceutical company. The Company discovers and develops monoclonal antibodies drugs for the treatment of inflammatory diseases. The company is based in Jena, Germany.
Latest IFRX News From Around the Web
Below are the latest news stories about INFLARX NV that investors may wish to consider to help them evaluate IFRX as an investment opportunity.
InflaRx N.V. (IFRX) Loses -47.13% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerInflaRx N.V. (IFRX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. |
InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma GangrenosumMulti-national, randomized, controlled adaptive Phase III study in ulcerative pyoderma gangrenosum (PG) initiated and first patient dosed in the U.S.PG is a rare and debilitating autoimmune skin disease characterized by painful ulcers that can rapidly progress JENA, Germany, Nov. 06, 2023 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biotechnology company pioneering anti-inflammatory therapeutics targeting the complement system, announced today that the first patient has been dosed in its P |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayIt's time to dive into the biggest pre-market stock movers for Friday with all the shares investors will want to keep an eye on today! |
InflaRx Reports Third Quarter 2023 Financial Results and Provides Business UpdateSingle ascending dose (SAD) Phase I data confirm best-in-class potential of orally available C5aR inhibitor INF904; multiple ascending dose (MAD) part ongoingSix clinical sites initiated; first patients screened in Phase III trial of vilobelimab in pyoderma gangrenosum (PG)FDA regulatory pathway towards BLA in broader acute respiratory distress syndrome (ARDS) indication discussed in encouraging FDA Type C meetingMAA for vilobelimab for treatment of SARS-CoV-2 induced septic ARDS in critically i |
12 Best German Stocks To Buy NowIn this piece, we will take a look at the 12 best German stocks to buy now. If you want to skip our overview of the German economy and how it has struggled as of late, then check out 5 Best German Stocks To Buy Now. The outbreak of the Russian invasion of Ukraine upended […] |
IFRX Price Returns
| 1-mo | -18.60% |
| 3-mo | -65.94% |
| 6-mo | -67.52% |
| 1-year | -45.74% |
| 3-year | -64.82% |
| 5-year | -95.38% |
| YTD | -54.84% |
| 2022 | -34.87% |
| 2021 | -5.37% |
| 2020 | 27.02% |
| 2019 | -89.11% |
| 2018 | 73.60% |
Loading social stream, please wait...